Table 1:

Demographic and clinical characteristics for patients discharged after stroke or TIA (2003 to 2013), with no adverse events for 90 days, and separately for those with stroke versus TIA as the entry event

CharacteristicEvent type; no. (%) of patientsStandardized difference*
Stroke or TIA
n = 26 366
Stroke
n = 15 950
TIA
n = 10 416
Age, yr, median (IQR)72 (60–80)72 (60–80)72 (61–81)0.03
Sex, female12 360 (46.9)7127 (44.7)5233 (50.2)0.11
Stroke type
 Stroke15 950 (60.5)15 950 (100.0)
 TIA10 416 (39.5)10 416 (100.0)
Clinical comorbidity
 Prior stroke3715 (14.1)2175 (13.6)1540 (14.8)0.03
 Prior acute MI2030 (7.7)1334 (8.4)696 (6.7)0.06
 Congestitve heart failure3563 (13.5)2295 (14.4)1268 (12.2)0.07
 Hypertension19 521 (74.0)12 282 (77.0)7239 (69.5)0.17
 Diabetes mellitus7741 (29.4)5004 (31.4)2737 (26.3)0.11
 Hyperlipidemia5232 (19.8)2964 (18.6)2268 (21.8)0.08
 Atrial fibrillation4591 (17.4)3254 (20.4)1337 (12.8)0.20
Canadian Neurological Scale Group19
 Mild (≥ 8)22 364 (86.3)12 355 (78.6)10 009 (98.1)0.64
 Moderate (5–7)2531 (9.8)2374 (15.1)157 (1.5)0.51
 Severe (0–4)1021 (3.9)983 (6.3)38 (0.4)0.33
Admission to registry hospital15 901 (60.3)13 153 (82.5)2748 (26.4)1.36
tPA on admission2275 (8.6)2255 (14.1)20 (0.2)0.56
Discharge medications
 Antiplatelet agents21 348 (81.0)12 907 (80.9)8441 (81.0)0.01
 Warfarin4238 (16.1)3157 (19.8)1081 (10.4)0.27
 All anticoagulants5422 (20.6)4215 (26.4)1207 (11.6)0.39
 Antithrombotics24 192 (91.8)14 983 (93.9)9209 (88.4)0.20
CEA or CAS
 At 1 yr229 (0.9)137 (0.9)92 (0.9)0.01
 At 3 yr278 (1.3)170 (1.3)108 (1.3)0.01
 At 5 yr239 (1.5)138 (1.4)101 (1.8)0.01
  • Note: CAS = carotid artery stenting, CEA = carotid endarterectomy, IQR = interquartile range, MI = myocardial infarction, TIA = transient ischemic attack, tPA = tissue plasminogen activator.

  • * The standardized difference, used for subgroup comparisons, is the difference in means or proportions for matched pairs divided by the standard error; an imbalance was defined as an absolute value greater than 0.20 (small effect size).

  • For this characteristic, complete data were available for 25 916 of the patients: 15 712 in the group with stroke and 10 204 in the group with TIA.

  • The percentages for longitudinal analyses are based on the denominator of subcohorts with complete 1-, 3- or 5-year follow-up. The denominator at 1 year was the same as the full cohort: 26 366 total (15 950 with stroke and 10 416 with TIA). At 3 years, the subcohort denominator was 21 548 total (13 287 with stroke and 8261 with TIA), and at 5 years the subcohort denominator was 15 571 total (9894 with stroke and 5677 with TIA).